Applications of nanotechnology for immunology

Smith, Douglas M.; Simon, Jakub K.; Baker, James R.

doi:10.1038/nri3488

Cited by 617 publications

(458 citation statements)

References 142 publications

(121 reference statements)

Supporting

Mentioning

453

Contrasting

Unclassified

Order By: Relevance

“…These properties facilitate interactions with proteins and cell membranes, causing the adjuvant to remain at the site of injection 21, 22, 23. To shield the positive charges of AlO(OH), we prepared AlO(OH)‐polymer nanoparticles (APNs) easily by a vortex using a wheat‐like PEG derivative PEG‐poly(AGE‐Suc) (PpAS) previously synthesized in our group ( Figure 1 A,B) 24.…”

Section: Resultsmentioning

confidence: 99%

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8⁺ T Cell Responses

Jiang

Wang

et al. 2017

Advanced Science

View full text Add to dashboard Cite

Due to its safety and efficacy, aluminum hydroxide is used as an immune adjuvant in human vaccines for over 80 years. Being a Th2 stimulator, the classical gel‐like adjuvant, however, fails to generate CD8+ T cell responses, which are important for cancer vaccines. Here, aluminum hydroxide is turned from gel into nano‐sized vaccine carriers AlO(OH)‐polymer nanoparticles (APNs) to promote their lymphatic migration. After actively uptaken via scavenger receptor‐A by antigen‐presenting cells (APCs) resident in lymph nodes (LNs), APNs destabilize lysosomes resulting in efficient cytosolic delivery and cross‐presentation of antigens. It is demonstrated that administration of APNs loaded with ovalbumin (OVA) and CpG led to the codelivery of both cargos into APCs in LNs, leading to their activation and subsequent adaptive immunity. A prime‐boost strategy with low doses of OVA (1.5 µg) and CpG (0.45 µg) induces potent CD8+ T cell responses and dramatically prolongs the survival of B16‐OVA tumor‐bearing mice. More impressively, when using B16F10 lysates instead of OVA as antigen, substantial antitumor effects on B16F10 tumor model are observed by using APN‐CpG. These results suggest the great potential of APNs as vaccine carriers that activate CD8+ T cell responses and the bright prospect of aluminum adjuvant in a nanoparticle formulation.

show abstract

Section: Resultsmentioning

confidence: 99%

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8⁺ T Cell Responses

Jiang

Wang

et al. 2017

Advanced Science

View full text Add to dashboard Cite

show abstract

“…The potential for NPs to optimize vaccination has been examined extensively [2,59,60], as has the delivery of immune-suppressive agents by NPs [61,62]. This horizon has recently expanded to include the use of NPs to control immune pathology associated with severe inflammatory responses as well as in the restoration of peripheral immune tolerance.…”

Section: Therapeutic Immune Manipulation: Beyond Vaccinesmentioning

confidence: 99%

“…Nanotechnology is revolutionizing many aspects of modern medicine, including diagnostics and therapeutics [1,2]. The first nanoparticle (NP) therapy was approved by the FDA in 1989.…”

Section: Introductionmentioning

confidence: 99%

“…The first nanoparticle (NP) therapy was approved by the FDA in 1989. Subsequently, numerous NP therapies have been approved, most of which have focused on optimizing the safety and pharmacokinetic properties of small-molecule agents and hormones [2,3]. More recently, our increasing knowledge of the cellular subsets and regulatory roles of various members of immune system, combined with the emergence of safe, biocompatible nanoparticle platforms, is catalyzing the development of complex, highly adaptable, and programmable NP therapies that are predicted to revolutionize the standard of care of numerous disorders.…”

Section: Introductionmentioning

confidence: 99%

“…More recently, our increasing knowledge of the cellular subsets and regulatory roles of various members of immune system, combined with the emergence of safe, biocompatible nanoparticle platforms, is catalyzing the development of complex, highly adaptable, and programmable NP therapies that are predicted to revolutionize the standard of care of numerous disorders. For example, NPs may be engineered to specifically target cells of the mononuclear phagocyte system (MPS) for the purposes of restoring peripheral immune tolerance or to regulate aberrant monocyte activities during severe inflammation [2,[4][5][6][7]. Five-hundred-nanometer NPs with negative zeta potential can be harnessed to target circulating monocytes, reducing their potential for causing immune pathology in numerous experimental disease models including West Nile virus (WNV) encephalitis, myocardial infarction, and inflammatory bowel disease (IBD) [8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Harnessing Nanoparticles for Immune Modulation

Getts¹,

Shea²,

Miller³

et al. 2016

Trends in Immunology

View full text Add to dashboard Cite

Recent approaches using nanoparticles engineered for immune regulation have yielded promising results in preclinical models of disease. The number of nanoparticle therapies is growing, fueled by innovations in nanotechnology and advances in understanding of the underlying pathogenesis of immune-mediated diseases. In particular, recent mechanistic insight into the ways in which nanoparticles interact with the mononuclear phagocyte system and impact its function during homeostasis and inflammation have highlighted the potential of nanoparticle-based therapies for controlling severe inflammation while concurrently restoring peripheral immune tolerance in autoimmune disease. Here we review recent advances in nanoparticle-based approaches aimed at immune-modulation, and discuss these in the context of concepts in polymeric nanoparticle development, including particle modification, delivery and the factors associated with successful clinical deployment.

show abstract

Which Nanobasics Should Be Taught in Medical Schools?

Sunshine

Paller

2019

AMA Journal of Ethics

View full text Add to dashboard Cite

The progressive growth in nanotechnology approaches to diagnostics and therapeutics, especially for cancer, necessitates training physicians in nanoethics. This article explains why it is critical for medical education to include instruction in nanotechnology, nanomedicine, nanotoxicology, and nanoethics and suggests basic concepts educators can use to infuse curricula with this content.Joel C. Sunshine, MD, PhD is a third-year dermatology resident at Northwestern University Feinberg School of Medicine in Chicago, Illinois. He obtained MD and PhD degrees in biomedical engineering at Johns Hopkins University, where his research focused on nanoparticle development for nucleic acid delivery and immune stimulation. His current research focuses on engineering the immune system for dermatology applications using nanotechnology.

show abstract

Applications of nanotechnology for immunology

Cited by 617 publications

References 142 publications

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8⁺ T Cell Responses

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8⁺ T Cell Responses

Harnessing Nanoparticles for Immune Modulation

Which Nanobasics Should Be Taught in Medical Schools?

Contact Info

Product

Resources

About

Applications of nanotechnology for immunology

Cited by 617 publications

References 142 publications

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8+ T Cell Responses

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8+ T Cell Responses

Harnessing Nanoparticles for Immune Modulation

Which Nanobasics Should Be Taught in Medical Schools?

Contact Info

Product

Resources

About

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8⁺ T Cell Responses

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8⁺ T Cell Responses